Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar;43(3):185-196.
doi: 10.1007/s40261-022-01240-9. Epub 2023 Feb 25.

Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA

Andrew Blauvelt  1 , Nianwen Shi  2 , Najwa Somani  3 , Russel Burge  3   4 , Baojin Zhu  3 , Terri Ridenour  3 , Scott Kern  3 , Carolyn Lew  2 , Nicole Zimmerman  2 , Mwangi Murage  5
Affiliations

Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA

Andrew Blauvelt et al. Clin Drug Investig. 2023 Mar.

Abstract

Background and objective: Data on real-world healthcare costs for ixekizumab (IXE) and secukinumab (SEC) in biologic-experienced patients with psoriasis are limited. This study compared real-world costs and healthcare resource utilization between IXE and SEC in biologic-experienced patients with psoriasis over an 18-month follow-up period in the USA.

Methods: Adult patients with a diagnosis of psoriasis between 1 March, 2015 and 31 October, 2019 were identified using health insurance claims data from IBM Watson Health MarketScan®. The index date was the date of the first IXE or SEC claim. Biologic-experienced patients with one or more pre-period claims for biologic drugs were identified. Inverse probability of treatment weighting was used to reduce cohort imbalances. All-cause and psoriasis-related direct healthcare costs along with index drug costs were estimated during the follow-up and reported as per patient per month. Discount factors published by the Institute for Clinical and Economic Review were applied to psoriasis-related biologics to adjust pharmacy costs.

Results: A total of 411 IXE and 780 SEC users were included. After weighting, all-cause inpatient admissions were similar between IXE (9.5%) and SEC users (10.3%). Weighted, mean ± standard deviation per patient per month all-cause healthcare costs were higher in IXE users ($6670 ± $2910) than in SEC users ($6239 ± $3903; p = 0.049). Psoriasis-related and monthly index drug costs were higher in IXE users ($5609 ± $2009; p < 0.001 and $4688 ± $1994; p < 0.001, respectively) than in SEC users ($5095 ± $2291 and $3853 ± $1977, respectively). After Institute for Clinical and Economic Review adjustment, mean per patient per month all-cause ($4363 ± $2576 vs $4398 ± $3517) and psoriasis-related costs ($3302 ± $1264 vs $3253 ± $1504) were similar between the groups. Institute for Clinical and Economic Review- and adherence-adjusted mean per patient per month index drug costs were similar between IXE and SEC users (p = 0.339).

Conclusions: Institute for Clinical and Economic Review-adjusted all-cause and psoriasis-related costs were comparable between IXE and SEC users among biologic-experienced patients over an 18-month follow-up period.

PubMed Disclaimer

Conflict of interest statement

Andrew Blauvelt has served as a scientific adviser and/or clinical study investigator for AbbVie, Abcentra, Aligos, Almirall, Amgen, Arcutis, Arena, Aslan, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, EcoR1, Eli Lilly and Company, Evommune, Forte, Galderma, Incyte, Janssen, Landos, Leo, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, UCB Pharma, and Vibliome. Nianwen Shi, Carolyn R. Lew, and Nicole M. Zimmerman are employees of IBM Watson Health who were compensated by Eli Lilly and Company for conducting this research. Najwa Somani, Scott A. Kern, Russel Burge, Terri Ridenour, Baojin Zhu, and Mwangi Murage are full-time employees and stockholders of Eli Lilly and Company.

Figures

Fig. 1
Fig. 1
Patient attrition. IXE ixekizumab, SEC secukinumab
Fig. 2
Fig. 2
a Mean all-cause and psoriasis (PsO)-related healthcare costs per patient per month (PPPM) before and after Institute for Clinical and Economic Review (ICER) adjustments; b ICER- and adherence-adjusted index drug costs. ICER Institute for Clinical and Economic Review, PPPM per patient per month, PsO psoriasis, USD US dollars
Fig. 3
Fig. 3
Quarterly Institute for Clinical and Economic Review (ICER)-adjusted all-cause healthcare costs, psoriasis (PsO)-related costs, and index drug costs. IXE ixekizumab, M month, PPPM per patient per month, SEC secukinumab, USD US dollars
See this image and copyright information in PMC

References

    1. Boehncke W-H, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–994. doi: 10.1016/S0140-6736(14)61909-7. - DOI - PubMed
    1. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–516. doi: 10.1016/j.jaad.2013.11.013. - DOI - PubMed
    1. Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States: a systematic review. JAMA Dermatol. 2015;151(6):651–658. doi: 10.1001/jamadermatol.2014.3593. - DOI - PubMed
    1. Kimball AB, et al. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6(6):383–392. doi: 10.2165/00128071-200506060-00005. - DOI - PubMed
    1. Bagel J, et al. Dose escalation and associated costs in biologic treatment of psoriasis based on real-world data. J Med Econ. 2021;24(1):782–791. doi: 10.1080/13696998.2021.1937187. - DOI - PubMed